New drugs to improve transplant outcomes

被引：34

作者：

First, MR ^{[1
]}

Fitzsimmons, WE ^{[1
]}

机构：

[1] Fujisawa Healthcare Inc, Deerfield, IL 60015 USA

来源：

TRANSPLANTATION | 2004年 / 77卷 / 09期

关键词：

D O I：

10.1097/01.TP.0000126934.97815.2E

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Fujisawa is committed to improving the outcomes of transplant patients worldwide. Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies. These programs are targeted to address many of the unmet medical needs in transplantation including (1) improving compliance, (2) reducing chronic rejection, and (3) improving long-term safety by reducing infectious and cardiovascular risk.

引用

页码：S88 / S92

页数：5

共 49 条

[1]

Chan MA, 1999, PHYTOTHER RES, V13, P464, DOI 10.1002/(SICI)1099-1573(199909)13:6&lt

[2]

464::AID-PTR483&gt

[3]

3.0.CO

[4]

2-4